Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

NCT04394624 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision, the decision is not related to any safety concern.

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: SAR408701
DRUG: ramucirumab
DRUG: pembrolizumab

Sponsor

Sanofi